Development of Y2O3:Eu@SiO2 Nanoparticle for Radiation-Enhanced Cancer Treatment
Session Number
Project ID: MEDH 38
Advisor(s)
Dr. Chin-Tu Chen; University of Chicago, Department of Radiology
Hannah Zhang; University of Chicago, Department of Radiology
Discipline
Medical and Health Sciences
Start Date
19-4-2023 9:35 AM
End Date
19-4-2023 9:50 AM
Abstract
Yttrium oxide (Y2O3) has potential in cancer theranostics when combined with radiation to generate reactive oxygen species (ROS) that damage cells. Our goal is to create silica-coated Y2O3 nanoparticles (Y2O3:Eu@SiO2) to improve tumor treatment through radiation. Y2O3:Eu nanoparticles (NP) were first synthesized and coated with silica shells. Their core sizes, shell thicknesses, and morphology were measured. Next, the antibody against tumor surface protein Interleukin13 receptor a2 (IL13Ra2) was conjugated to Y2O3:Eu@SiO2 to produce NPs that target cancer (NP-AbIL13Ra2). An enzyme-linked-sandwich-assay was performed, and the NPs’ ability to generate radiation-induced ROS was also confirmed. Y2O3:Eu@SiO2 has a shepherd shape with a mean core size of 133nm and a mean coating size of 7nm. NP-AbIL13Ra2 showed similar binding activity to purified IL13Ra2 antibody standard. NP-AbIL13Ra2 exhibited 2.3 fold higher ROS production compared to PBS only, with a ratio increase from 1 at 0 Gy to 4.24 at 8 Gy. The Y2O3:Eu@SiO2 nanoparticles have been successfully synthesized and are ready to be used as a theranostic agent with active functional groups. Further research will evaluate their potential in-vitro with cancer cells and in-vivo efficacy in animal tumor models to assess clinical applications.
Development of Y2O3:Eu@SiO2 Nanoparticle for Radiation-Enhanced Cancer Treatment
Yttrium oxide (Y2O3) has potential in cancer theranostics when combined with radiation to generate reactive oxygen species (ROS) that damage cells. Our goal is to create silica-coated Y2O3 nanoparticles (Y2O3:Eu@SiO2) to improve tumor treatment through radiation. Y2O3:Eu nanoparticles (NP) were first synthesized and coated with silica shells. Their core sizes, shell thicknesses, and morphology were measured. Next, the antibody against tumor surface protein Interleukin13 receptor a2 (IL13Ra2) was conjugated to Y2O3:Eu@SiO2 to produce NPs that target cancer (NP-AbIL13Ra2). An enzyme-linked-sandwich-assay was performed, and the NPs’ ability to generate radiation-induced ROS was also confirmed. Y2O3:Eu@SiO2 has a shepherd shape with a mean core size of 133nm and a mean coating size of 7nm. NP-AbIL13Ra2 showed similar binding activity to purified IL13Ra2 antibody standard. NP-AbIL13Ra2 exhibited 2.3 fold higher ROS production compared to PBS only, with a ratio increase from 1 at 0 Gy to 4.24 at 8 Gy. The Y2O3:Eu@SiO2 nanoparticles have been successfully synthesized and are ready to be used as a theranostic agent with active functional groups. Further research will evaluate their potential in-vitro with cancer cells and in-vivo efficacy in animal tumor models to assess clinical applications.